Cargando…

Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma

BACKGROUND: The involvement of lipid metabolism in tumourigenesis and the progression of clear cell renal cell carcinoma (ccRCC) have been reported. However, the role of phospholipid profile alterations in ccRCC has not yet been systematically explored. In the present study, we compared the phosphol...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Yiqing, Wang, Qiang, Zhang, Xingzhong, Wang, Xiaofeng, Qin, Caipeng, Sheng, Zhengzuo, Yin, Huaqi, Jiang, Changtao, Li, Jing, Xu, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427523/
https://www.ncbi.nlm.nih.gov/pubmed/28494778
http://dx.doi.org/10.1186/s13046-017-0525-1
_version_ 1783235643552301056
author Du, Yiqing
Wang, Qiang
Zhang, Xingzhong
Wang, Xiaofeng
Qin, Caipeng
Sheng, Zhengzuo
Yin, Huaqi
Jiang, Changtao
Li, Jing
Xu, Tao
author_facet Du, Yiqing
Wang, Qiang
Zhang, Xingzhong
Wang, Xiaofeng
Qin, Caipeng
Sheng, Zhengzuo
Yin, Huaqi
Jiang, Changtao
Li, Jing
Xu, Tao
author_sort Du, Yiqing
collection PubMed
description BACKGROUND: The involvement of lipid metabolism in tumourigenesis and the progression of clear cell renal cell carcinoma (ccRCC) have been reported. However, the role of phospholipid profile alterations in ccRCC has not yet been systematically explored. In the present study, we compared the phospholipid compositions between ccRCC and paired normal renal tissues. METHODS: The phospholipid compositions of paired ccRCC and normal renal tissues were evaluated using liquid chromatography tandem mass spectrometry (LC/MS/MS). To evaluate the mRNA and protein levels of lysophosphatidylcholine acyltransferase (LPCAT), which converts lysophosphatidylcholine (LPC) to phosphatidylcholine (PC), qRT-PCR, western blotting and immunohistochemistry were performed. The correlations of LPCAT1 expression with clinicopathological features and prognosis were assessed. In addition, siRNAs were used to knockdown LPCAT1 expression in ccRCC cell lines, and its effect on cell proliferation, cell cycle, migration and invasion were investigated. RESULTS: The phospholipid compositions of ccRCC and normal renal tissues were significantly different. Multiple LPC species were decreased and corresponding PC species were increased in cancer tissues. The mRNA and protein levels of LPCAT1 were up-regulated in ccRCC tissues compared with normal renal tissues, and LPCAT1 expression was significantly correlated with unfavourable pathological features (higher tumour grade, higher TNM stage and larger tumour size) and overall survival. In cell line experiments, LPCAT1 knockdown depleted PCs, inhibited cell proliferation, migration and invasion and induced cell cycle arrest at the G0/G1 phase. CONCLUSION: Selective changes in PC and LPC composition were observed in ccRCC tissues. The overexpression of LPCAT1 promotes the development and progression of ccRCC, likely through the conversion of LPC to PC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13046-017-0525-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5427523
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54275232017-05-12 Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma Du, Yiqing Wang, Qiang Zhang, Xingzhong Wang, Xiaofeng Qin, Caipeng Sheng, Zhengzuo Yin, Huaqi Jiang, Changtao Li, Jing Xu, Tao J Exp Clin Cancer Res Research BACKGROUND: The involvement of lipid metabolism in tumourigenesis and the progression of clear cell renal cell carcinoma (ccRCC) have been reported. However, the role of phospholipid profile alterations in ccRCC has not yet been systematically explored. In the present study, we compared the phospholipid compositions between ccRCC and paired normal renal tissues. METHODS: The phospholipid compositions of paired ccRCC and normal renal tissues were evaluated using liquid chromatography tandem mass spectrometry (LC/MS/MS). To evaluate the mRNA and protein levels of lysophosphatidylcholine acyltransferase (LPCAT), which converts lysophosphatidylcholine (LPC) to phosphatidylcholine (PC), qRT-PCR, western blotting and immunohistochemistry were performed. The correlations of LPCAT1 expression with clinicopathological features and prognosis were assessed. In addition, siRNAs were used to knockdown LPCAT1 expression in ccRCC cell lines, and its effect on cell proliferation, cell cycle, migration and invasion were investigated. RESULTS: The phospholipid compositions of ccRCC and normal renal tissues were significantly different. Multiple LPC species were decreased and corresponding PC species were increased in cancer tissues. The mRNA and protein levels of LPCAT1 were up-regulated in ccRCC tissues compared with normal renal tissues, and LPCAT1 expression was significantly correlated with unfavourable pathological features (higher tumour grade, higher TNM stage and larger tumour size) and overall survival. In cell line experiments, LPCAT1 knockdown depleted PCs, inhibited cell proliferation, migration and invasion and induced cell cycle arrest at the G0/G1 phase. CONCLUSION: Selective changes in PC and LPC composition were observed in ccRCC tissues. The overexpression of LPCAT1 promotes the development and progression of ccRCC, likely through the conversion of LPC to PC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13046-017-0525-1) contains supplementary material, which is available to authorized users. BioMed Central 2017-05-12 /pmc/articles/PMC5427523/ /pubmed/28494778 http://dx.doi.org/10.1186/s13046-017-0525-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Du, Yiqing
Wang, Qiang
Zhang, Xingzhong
Wang, Xiaofeng
Qin, Caipeng
Sheng, Zhengzuo
Yin, Huaqi
Jiang, Changtao
Li, Jing
Xu, Tao
Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma
title Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma
title_full Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma
title_fullStr Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma
title_full_unstemmed Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma
title_short Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma
title_sort lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427523/
https://www.ncbi.nlm.nih.gov/pubmed/28494778
http://dx.doi.org/10.1186/s13046-017-0525-1
work_keys_str_mv AT duyiqing lysophosphatidylcholineacyltransferase1upregulationandconcomitantphospholipidalterationsinclearcellrenalcellcarcinoma
AT wangqiang lysophosphatidylcholineacyltransferase1upregulationandconcomitantphospholipidalterationsinclearcellrenalcellcarcinoma
AT zhangxingzhong lysophosphatidylcholineacyltransferase1upregulationandconcomitantphospholipidalterationsinclearcellrenalcellcarcinoma
AT wangxiaofeng lysophosphatidylcholineacyltransferase1upregulationandconcomitantphospholipidalterationsinclearcellrenalcellcarcinoma
AT qincaipeng lysophosphatidylcholineacyltransferase1upregulationandconcomitantphospholipidalterationsinclearcellrenalcellcarcinoma
AT shengzhengzuo lysophosphatidylcholineacyltransferase1upregulationandconcomitantphospholipidalterationsinclearcellrenalcellcarcinoma
AT yinhuaqi lysophosphatidylcholineacyltransferase1upregulationandconcomitantphospholipidalterationsinclearcellrenalcellcarcinoma
AT jiangchangtao lysophosphatidylcholineacyltransferase1upregulationandconcomitantphospholipidalterationsinclearcellrenalcellcarcinoma
AT lijing lysophosphatidylcholineacyltransferase1upregulationandconcomitantphospholipidalterationsinclearcellrenalcellcarcinoma
AT xutao lysophosphatidylcholineacyltransferase1upregulationandconcomitantphospholipidalterationsinclearcellrenalcellcarcinoma